{"schema_version":"secwatch.filing_event.v1","accession":"0001829126-25-009221","form_type":"8-K","ticker":"NTHI","cik":"0001979414","company_name":"NEONC TECHNOLOGIES HOLDINGS, INC.","filed_at":"2025-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:41.205480+00:00","generated_at":"2026-05-16T19:57:05.651307+00:00","sec_items":["2.02","5.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"NeOnc Q3 net loss $8.6M ($0.45/diluted); NEO100 Phase 2a shows 21% response rate; board changes","bullets":["Net loss of $8.6M ($0.45 diluted EPS) vs $2.2M ($0.12) in Q3 2024; G&A up $903k vs $244k YoY.","NEO100 Phase 2a in recurrent brain cancer: 21% response rate vs <8% historical; 44% six-month PFS; 33% alive >=18 months.","NEO212 received FDA authorization to proceed to Phase II; Phase I final cohort dosing on track for Q4 2025.","NuroMENA subsidiary signed $50M strategic partnership with Quazar Investment, appointed H.H. Sheikh Nahyan as Exec Chairman.","Dr. Ming-Fu Chiang re-elected to Board after Ishwar K. Puri resigned due to USC objection."],"urls":{"canonical":"https://secwatch.observer/filing/0001829126-25-009221","json":"https://secwatch.observer/filing/0001829126-25-009221.json","markdown":"https://secwatch.observer/filing/0001829126-25-009221.md","text":"https://secwatch.observer/filing/0001829126-25-009221.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1979414/000182912625009221/0001829126-25-009221-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1979414/000182912625009221/neonctechnologies_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T19:57:05.651307+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}